Brief: Respiratorius: FDA grants Orphan Drug Designation for VAL001

Respiratorius AB (publ)

03/04/2017 11:12

April 3 (Reuters) - RESPIRATORIUS AB (PUBL)  RESPS.ST : 
    * SAYS HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY US FOOD 
AND DRUG ADMINISTRATION (FDA) FOR VALPROIC ACID FOR THE 
TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA 
    * A CLINICAL PHASE I/IIA STUDY OF VAL001 IS UNDERWAY AND 
EXPECTED TO BE REPORTED IN H1 2018 
 
     
 Source text: http://bit.ly/2oQ0sBL 
     
 Further company coverage:  RESPS.ST   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))